ADARx secures $200m to advance clinical programs

ADARx Pharmaceuticals has concluded an oversubscribed Series C financing, securing $200m for advancing its clinical programmes, including ADX-324 and ADX-038.

Led jointly by TCGX and Bain Capital Life Sciences, the financing round witnessed participation from new investors such as Commodore Capital, Cormorant Asset Management, Invus, Marshall Wace, Redmile Group, HBM Healthcare Investments and Blackrock.